Enliven Therapeutics (ELVN) Net Cash Flow (2019 - 2026)
Enliven Therapeutics has reported Net Cash Flow over the past 8 years, most recently at $33.3 million for Q1 2026.
- Quarterly results put Net Cash Flow at $33.3 million for Q1 2026, up 248.17% from a year ago — trailing twelve months through Mar 2026 was $30.5 million (up 164.15% YoY), and the annual figure for FY2025 was -$25.3 million, down 205.42%.
- Net Cash Flow reached $33.3 million in Q1 2026 per ELVN's latest filing, up from -$2.8 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $216.6 million in Q1 2023 and bottomed at -$166.4 million in Q2 2023.
- Median Net Cash Flow over the past 5 years was -$6.3 million (2022), compared with a mean of $1.3 million.
- Peak annual rise in Net Cash Flow hit 2234.5% in 2023, while the deepest fall reached 2141.81% in 2023.
- Over 5 years, Net Cash Flow stood at -$10.6 million in 2022, then surged by 347.52% to $26.3 million in 2023, then fell by 10.64% to $23.5 million in 2024, then tumbled by 112.07% to -$2.8 million in 2025, then soared by 1273.77% to $33.3 million in 2026.
- Business Quant data shows Net Cash Flow for ELVN at $33.3 million in Q1 2026, -$2.8 million in Q4 2025, and -$17.7 million in Q3 2025.